AHA March 26 submitted comments on a discussion draft of the SUSTAIN 340B Act, legislation proposed in the Senate to clarify Congress’ intent in creating the 340B program and protect 340B providers from egregious behavior by drug companies, insurers and pharmacy benefit managers.  

“Their unlawful and pernicious practices have collectively undermined the 340B program and harmed patient care,” AHA wrote. “At the same time, we have concerns regarding other aspects of this discussion draft that should be better aligned to reflect the operational realities that 340B hospitals face every day. Therefore, our comments primarily focus on how Congress can ensure that the 340B program continues to benefit patients and communities, while protecting against any unnecessary harm or burden that would jeopardize patient care.” 

Headline
The AHA provided a statement to the House Energy and Commerce Subcommittee on Health today for a hearing titled “Lowering Health Care Costs for All Americans:…
Headline
The House Appropriations Committee June 4 released the fiscal year 2027 appropriations bill for the Departments of Labor, Health and Human Services, Education…
Headline
Eli Lilly said June 1 it will deny 340B Drug Pricing Program discounts to providers that do not meet its documentation requirements by next week.In a statement…
Headline
The 4th U.S. Circuit Court of AppealsMay 28 agreed to rehear challenges to 340B contract pharmacy laws from West Virginia and Maryland. In April, a three-judge…
Headline
Rep. Randy Feenstra, R-Iowa, introduced the Rural Maternity Options for Medical Support Act on May 19. The bill would guarantee that beds used solely for labor…
Headline
The House Education and Workforce Committee May 21 unanimously passed the Transparency in Billing Act (H.R. 8684). The bill would require off-campus hospital…